Estrogen Treatment in Acromegalic Women

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00315107

Enrollment

Registered

2006-04-17

Start date

2006-05-31

Completion date

2007-08-31

Last updated

2006-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Brief summary

Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

Detailed description

This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Interventions

DRUGAlesse

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women 18 years and older treated with somatostatin analogs * Active acromegaly

Exclusion criteria

* Cardiovascular or cerebrovascular disease * Thrombophlebitis or thromboembolism * Breast cancer * Non-controlled arterial hypertension * Smoking * Pregnancy or lactation

Countries

Canada

Contacts

Primary ContactOmar SERRI, MD

omar.serri@umontreal.ca514-890-8000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026